I used Sibelium because my migraines were arriving most weekends. The attacks became less frequent, but I felt sleepy in the mornings during the first part of treatment.
Sibelium
Sibelium is a flunarizine tablet for people who need preventive treatment for recurrent migraine or selected vestibular symptoms. Its key benefit is reducing excessive calcium entry into nerve and vascular cells, which may lower susceptibility to future episodes.
Description
Sibelium is an oral tablet containing flunarizine, used mainly to help prevent migraine attacks and manage selected vestibular symptoms such as vertigo. It is intended for preventive treatment rather than immediate relief once a migraine has started. Flunarizine reduces excessive calcium entry into nerve and vascular cells, which may lower migraine susceptibility.
Composition
Sibelium contains flunarizine, supplied as flunarizine hydrochloride in pharmaceutical formulations. Flunarizine belongs to the calcium-channel-blocking group used in neurological therapy.
Dosage and usage
Sibelium is taken by mouth as tablets. The strength selected by the prescriber depends on age, migraine pattern, treatment response, adverse effects, and other medicines being used.
The product card identifies the available presentation. Dose selection should follow the prescribed regimen rather than a dose used by another patient.
- Take the tablet at the scheduled time.
- Swallow it with water.
- It may be taken with or without food unless the prescriber gives different instructions.
- Do not take extra tablets after a missed dose.
- If a dose is forgotten, take it when remembered unless the next scheduled dose is close.
- Do not double the next dose.
- Do not stop long-term preventive treatment suddenly without a treatment plan.
Flunarizine can cause drowsiness in some patients. Taking the tablet in the evening may be chosen by the prescriber when sedation occurs, though the timing should match the prescribed instructions.
How it works
Its action reduces excessive calcium influx into cells and may limit processes involved in migraine susceptibility [1].
Migraine involves more than a blood-vessel problem. Changes in nerve signalling, sensory processing, inflammatory mediators, and trigeminal pathways can all contribute. Flunarizine is used as a preventive agent because it can dampen neuronal excitability over time rather than simply numb pain after an attack begins.
The medicine is not a triptan and does not act as an immediate serotonin-based rescue treatment. It also differs from beta blockers and antiseizure medicines, which prevent migraine through other physiological pathways.
Indications
Sibelium is a flunarizine tablet used in preventive neurological treatment. Doctors may prescribe it for recurrent migraine, especially when attacks are frequent or disruptive, and for selected balance disorders involving dizziness or vertigo. A vestibular disorder affects the inner-ear balance system or its connections with the brain.
Preventive Treatment for Migraine Attacks
Migraine prevention aims to reduce the number of attacks, shorten their duration, or make symptoms easier to manage. Flunarizine may be considered when migraine episodes recur often, interfere with work or sleep, or respond poorly to acute treatment.
Patients may still experience occasional headaches during treatment. A reduction in frequency is a more realistic goal than the complete disappearance of every attack. A headache diary can help a prescriber assess whether the treatment is producing a meaningful change.
Management of Vestibular Vertigo and Dizziness
Vertigo is a false sensation that the surroundings are moving or spinning. Flunarizine has been used in some vestibular conditions, but the cause of dizziness must be established before preventive treatment is selected.
Dizziness caused by dehydration, low blood pressure, an ear disorder, medication effects, or a neurological condition may require a different approach. Sudden dizziness with weakness, difficulty speaking, fainting, severe headache, or loss of coordination requires urgent medical assessment.
Comparison
The most useful comparison is by pharmacological approach rather than by commercial brand.
| Preventive approach | Main clinical role | Common limitation |
|---|---|---|
| Flunarizine tablets | Reducing migraine susceptibility and selected vestibular symptoms | Drowsiness, weight gain, mood changes, or movement symptoms may limit use |
| Beta-blocker therapy | Migraine prevention, especially with some cardiovascular indications | May worsen asthma, slow the pulse, or reduce exercise tolerance |
| Antiseizure therapy | Migraine prevention when neurological factors support its use | Cognitive effects, sensory symptoms, or other medicine-specific reactions can occur |
Flunarizine may be considered when a calcium-channel-modulating approach is appropriate. A beta blocker may fit a patient who also has a compatible cardiovascular indication. An antiseizure medicine may be preferred when the clinical history supports that option.
No preventive drug is suitable for every patient. The choice depends on pregnancy status, depression history, movement symptoms, blood pressure, asthma, kidney or liver function, and the pattern of migraine.
Contraindications
Sibelium is not suitable for everyone. The medicine requires careful selection when the patient has a history of depressive illness, Parkinsonian symptoms, tremor, or other extrapyramidal disorders.
Sedatives, sleep medicines, opioid analgesics, some antihistamines, and alcohol can increase central nervous system depression. Antidepressants and tranquilizers require a medication review because the combined effects may include greater drowsiness, changes in mood, or difficulty identifying which medicine is causing an adverse reaction.
Tell the prescriber about every medicine used for migraine, depression, anxiety, sleep, epilepsy, blood pressure, and dizziness. Duplicate flunarizine therapy can cause an unintended excess dose if two products with the same active ingredient are taken together.
The South African Health Products Regulatory Authority and other national regulators treat medicine-specific warnings as clinically relevant information, while the WHO classification places flunarizine within the neurological and cardiovascular pharmacological framework [2].
When this is not for you
This Medication Is Not for You If
Flunarizine should generally be avoided or reassessed when a patient:
- Has current depression or a previous depressive episode linked to treatment.
- Has Parkinson’s disease or another movement disorder.
- Has experienced drug-induced tremor, stiffness, or abnormal involuntary movements.
- Has a known allergy to flunarizine or an excipient in the tablet.
- Is pregnant or breastfeeding unless a prescriber has specifically assessed the clinical need.
- Has unexplained dizziness that may represent an urgent neurological or cardiovascular problem.
Side effects
The recognised adverse effects of flunarizine include sleepiness, fatigue, increased appetite, weight gain, nausea, and mood changes. Some patients experience insomnia or other sleep disturbance. The frequency and severity vary between individuals and may increase with prolonged exposure.
Commonly reported problems include:
- Drowsiness or slowed alertness.
- Tiredness and reduced energy.
- Increased appetite or weight gain.
- Nausea or stomach discomfort.
- Low mood or depressive symptoms.
- Sleep disturbance.
- Muscle stiffness, tremor, or other movement changes.
Weight gain can develop gradually. A patient may notice tighter clothing before recognising a change on the scale. Recording appetite and weight from the beginning gives the prescriber a clearer baseline.
Drowsiness can affect driving, cycling, operating machinery, and work requiring sustained attention. Alcohol and other sedating medicines may intensify this effect.
Depression is a clinically significant warning. New low mood, loss of interest, social withdrawal, hopelessness, or thoughts of self-harm should be reported urgently. Flunarizine may also cause extrapyramidal symptoms, meaning abnormal movement, stiffness, tremor, restlessness, or slowed movement. These reactions need prompt medical review.
A further practical issue concerns alcohol. Alcohol may worsen sleepiness and impaired concentration, making driving unsafe even when the tablet itself initially seemed well tolerated.
Common mistakes
Several avoidable mistakes can reduce the value of preventive treatment or increase risk.
- Using Sibelium as an immediate rescue tablet after a migraine has already begun.
- Taking an extra tablet after forgetting whether the scheduled dose was taken.
- Combining two flunarizine-containing products.
- Continuing treatment despite new depression, tremor, stiffness, or marked sleepiness.
- Stopping after a few days because the migraine pattern has not changed yet.
- Drinking alcohol while testing personal tolerance to the medicine.
- Driving before knowing whether the tablet causes sedation.
- Failing to mention antidepressants, tranquilizers, sleep medicines, or sedating allergy treatments.
- Assuming every episode of dizziness is caused by migraine.
- Treating weight gain as unrelated when it began soon after treatment.
One overlooked mistake is judging success only by pain intensity. Fewer migraine days, less vomiting, shorter attacks, or reduced need for acute medicine may represent clinically meaningful improvement.
What doctors say
In clinical practice, doctors usually judge Sibelium by the number of migraine days over time, not by whether one headache disappears after a tablet. Preventive treatment needs a fair observation period unless a serious adverse reaction appears earlier.
A prescriber will often ask about sleepiness, appetite, weight, mood, tremor, stiffness, and changes in walking. Those questions are not routine paperwork. They help detect adverse effects that can develop gradually and may be overlooked by the patient.
The main benefit is preventive control. The main trade-off is tolerability, especially in people vulnerable to depression, weight gain, sedation, or movement symptoms. The European Medicines Agency’s general pharmacovigilance principles support monitoring for adverse reactions that emerge during continued use, even when the initial treatment response is favourable [3].
A migraine diary remains useful after improvement. Fewer attacks can lead patients to forget how severe the original pattern was, which makes later treatment decisions less precise.
Frequently asked questions
How long does Sibelium take to help prevent migraine?
Flunarizine is a preventive treatment, so its effect is assessed over several weeks rather than after one tablet. NICE guidance on headache management, reviewed in 2025, supports using treatment response and headache frequency to judge preventive benefit [4]. A severe adverse reaction should not be ignored while waiting for a preventive effect.
Can Sibelium stop a migraine that has already started?
Sibelium is not designed to provide rapid relief during an acute migraine attack. Its purpose is to reduce future migraine susceptibility through regular preventive treatment. The International Headache Society distinguishes preventive therapy from acute treatment in its 2018 International Classification of Headache Disorders [5].
Can Sibelium cause weight gain?
Weight gain and increased appetite are recognised problems with flunarizine. The change may be gradual, so monitoring appetite, clothing fit, and body weight can help identify it early. A prescriber may reassess the treatment if the change is substantial or continues. European Medicines Agency guidance from 2023 supports monitoring and reporting suspected adverse reactions during treatment.
Can Sibelium affect mood?
Yes. Depressive symptoms are a clinically important adverse reaction associated with flunarizine. Anyone who develops persistent sadness, loss of interest, hopelessness, or thoughts of self-harm needs urgent medical attention rather than continued self-management. European Medicines Agency pharmacovigilance guidance from 2023 supports prompt assessment of suspected medicine-related mood reactions.
Can Sibelium cause sleepiness?
Sleepiness and fatigue can occur, especially during the early phase of treatment or when flunarizine is combined with alcohol or other sedating medicines. Avoid driving or hazardous work until the individual response is clear. Evening administration may reduce daytime inconvenience when that timing is consistent with the prescribed regimen. European Medicines Agency guidance from 2023 identifies sedation as an adverse effect that should be monitored clinically.
Can Sibelium be taken with antidepressants or tranquilizers?
A medicine review is needed before combining flunarizine with antidepressants, tranquilizers, sleeping medicines, opioids, or sedating antihistamines. The combination may increase drowsiness and can complicate the assessment of mood-related adverse effects. Do not change psychiatric treatment abruptly to accommodate migraine prevention. European Medicines Agency guidance from 2023 supports reviewing possible interactions and overlapping adverse effects.
Is Sibelium suitable for vertigo?
Flunarizine has been used for selected vestibular symptoms, including vertigo, but dizziness has many possible causes. The treatment is more appropriate when the clinical assessment supports a vestibular or migraine-related mechanism. New neurological signs, fainting, severe imbalance, or sudden severe headache require urgent assessment. European Medicines Agency guidance from 2023 supports evaluating the suspected cause before attributing a symptom to treatment.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Comparison
Sibelium: Reviews and Experiences
The tablet helped reduce the number of severe headaches over a few months. My appetite increased, and I had to pay closer attention to evening snacking.
I stopped after noticing low mood and a heavy, slowed feeling. My doctor changed the preventive plan, and the mood symptoms improved after the medicine was withdrawn.
Dizziness was my main complaint rather than headache. Sibelium seemed helpful for a while, although the cause of the dizziness still needed proper assessment.
Sources
- WHO Collaborating Centre for Drug Statistics Methodology (2025). ATC/DDD Index — flunarizine entry
- South African Health Products Regulatory Authority (2022). Approved professional information for flunarizine-containing tablets
- European Medicines Agency (2023). Guideline on good pharmacovigilance practices (GVP)
- National Institute for Health and Care Excellence (2025). Headaches in over 12s: diagnosis and management
- International Headache Society (2018). The International Classification of Headache Disorders, 3rd edition (ICHD-3)